Translational potential of allosteric modulators targeting the cannabinoid CB 1 receptor
Reads0
Chats0
TLDR
This paper reviews and summarizes the complex pharmacological profiles of each class of CB1 allosteric modulators, the development of new classes of CB 1 allosterics modulators and the results from in vivo assessments of their therapeutic value.Abstract:
The cannabinoid type-1 (CB1) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiological processes. Historically, drug discovery efforts targeting the CB1 receptor have focused on the development of orthosteric ligands that interact with the active site to which endogenous cannabinoids bind. Research performed over the last several decades has revealed substantial difficulties in translating CB1 orthosteric ligands into druggable candidates. The difficulty is mainly due to the adverse effects associated with orthosteric CB1 ligands. Recent discoveries of allosteric CB1 modulators provide tremendous opportunities to develop CB1 ligands with novel mechanisms of action; these ligands may potentially improve the pharmacological effects and enhance drug safety in treating the disorders by regulating the functions of the CB1 receptor. In this paper, we review and summarize the complex pharmacological profiles of each class of CB1 allosteric modulators, the development of new classes of CB1 allosteric modulators and the results from in vivo assessments of their therapeutic value.read more
Citations
More filters
Journal ArticleDOI
Cannabidiol (CBD) as a Promising Anti-Cancer Drug
TL;DR: The most recent findings that strongly support the further development of CBD as a promising anti-cancer drug are discussed.
Journal ArticleDOI
Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow
TL;DR: The main psychoactive content in cannabis is Δ 9 -tetrahydrocannabinol (THC), and there are two classes of cannabinoids—the synthetic cannabi-noids (e.g., WIN55212–2) and the endogenous cannabinoids (eCB), anandamide (ANA) and 2-arachidonoylglycerol (2-AG).
Journal ArticleDOI
Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities.
Szymon Hryhorowicz,Marta Kaczmarek-Ryś,Angelika Andrzejewska,Klaudia Staszak,Magdalena Hryhorowicz,Aleksandra Korcz,Ryszard Słomski +6 more
TL;DR: Structural essentials of the cannabinoid 1 receptor- ligand (drug) interactions, as well as modes of CB1R signaling regulation are focused on.
Journal ArticleDOI
Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1
Xin Yang,Xuehui Wang,Zheng Xu,Chao Wu,Yangli Zhou,Yifei Wang,Guifeng Lin,Kan Li,Ming Wu,Anjie Xia,Jingming Liu,Lin Cheng,Jun Zou,Wei Yan,Zhenhua Shao,Sheng-Hsiung Yang +15 more
TL;DR: The crystallographic and cryo-EM structures of CB1 bound to the positive allosteric modulator ZCZ011 revealallosteric modulation ofCB1 by rearrangement of the TM2 and TM3 transmembrane domains.
Journal ArticleDOI
Mechanisms of endocannabinoid control of synaptic plasticity.
TL;DR: In this article, the retrograde action of endocannabinoids at CB1 receptors (CB1Rs) at the post-synaptic neuron has been investigated and a review of the current understanding and new advances in this area is presented.
References
More filters
Journal ArticleDOI
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TL;DR: A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
Journal ArticleDOI
Pharmacology of cannabinoid cb1 and cb2 receptors
TL;DR: This review focuses on the classification, binding properties, effector systems and distribution of cannabinoid receptors, and describes the various cannabinoid receptor agonists and antagonists now available and considers the main in vivo and in vitro bioassay methods that are generally used.
Journal ArticleDOI
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Jonathan D. Urban,William P. Clarke,Mark von Zastrow,David E. Nichols,Brian K. Kobilka,Harel Weinstein,Jonathan A. Javitch,Bryan L. Roth,Arthur Christopoulos,Patrick M. Sexton,Keith J. Miller,Michael Spedding,Richard B. Mailman +12 more
TL;DR: Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.
Journal ArticleDOI
The endocannabinoid system and its therapeutic exploitation
TL;DR: The conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come are explored.
Journal ArticleDOI
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
Belén G. Ramírez,Cristina Blázquez,Teresa Gómez del Pulgar,Manuel Guzmán,María L. de Ceballos +4 more
TL;DR: It is shown that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microgoo activation.